Skip to main content
Equibles

NBTX · Nanobiotix S.A. · Metrics

Track NBTX — free

Use NBTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NBTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$25.10 -0.65 (-2.52%)
Rebalance outlook locked
Market Cap
$1.70B
Shares
50.92M
Volume · Oct 5 144.28K Avg daily vol (3M) 148.09K

NBTX metrics

58 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$25.75
Market cap
$1.70B

Price action

20 metrics
Price change (1W)
-22.7%
Price change (30D)
-33.6%
Price change (3M)
-32.9%
Price change (6M)
-17.0%
Price change (YTD)
+11.4%
Price change (1Y)
+29.5%
Trailing year
Price change (5Y)
+128.5%
52-week high
$55.07
52-week low
$15.08
Change from 52-week high
-53.2%
Change from 52-week low
+70.8%
Annualized volatility
102.5%
Annualized volatility (3M)
75.5%
Beta
2.3
RSI (14D)
25.1
Price vs SMA 50
-31.9%
Price vs SMA 200
-22.9%
Avg volume (3M)
148,090
Relative volume
1.7
Average dollar volume
$5.65M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
50.92M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
126.4×
reciprocal yield 0.8%
P / book
—
FCF yield
-2.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-04-01

Profitability

9 metrics
Gross margin
—
Operating margin
-256.8%
Trailing 12 months
Net margin
-459.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$29.55M
Net income (TTM)
−$61.67M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-305.9%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-1.75

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$13.42M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.1%
Year over year · more shares
Revenue CAGR (3Y)
+89.7%
Revenue CAGR (5Y)
+67.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-41.2%
Debt / equity
—
Current ratio
1.4
EBITDA (TTM)
—
Free cash flow (TTM)
−$41.06M
Quick ratio
1.4
Interest coverage
-1.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$61.91M
Total assets
$146.52M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$39.88M
Capital expenditures (TTM)
$1.18M
R&D (TTM)
$24.85M
SG&A (TTM)
—
Stock compensation (TTM)
$4.85M
R&D / revenue
185.2%
Stock compensation / revenue
36.1%

Ownership (13F)

3 metrics
13F filers
19
13F filer change QoQ
+4
Institutional ownership
11.4%

Short interest

3 metrics
Short interest
0.3%
Latest settlement · 1.4 days to cover
Days to cover
1.4d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1760854 CUSIP 63009J107 Visit website Investor relations